Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 10, Pages -Publisher
MDPI
DOI: 10.3390/ijms21103473
Keywords
4-hexylresorcinol; HUVEC; diabetes mellitus; TGF-beta 1; angiogenesis
Funding
- Cooperative Research Program for Agriculture Science and Technology Development Rural Development Administration, Republic of Korea [PJ01313902]
Ask authors/readers for more resources
4-Hexyl resorcinol (4HR) is an organic compound and has been used in skin care application. 4HR is an M2-type macrophage activator and elevates vascular endothelial growth factor (VEGF) expression via the hypoxia-inducible factor (HIF)-independent pathway. As endothelial cells are important in wound healing, the human umbilical vein endothelial cells (HUVECs) were treated with 4HR, and changes in VEGF-A, -C, and transforming growth factor-beta 1 (TGF-beta 1) expression were investigated. The administration of 4HR increased the expression level of VEGF-A, -C, and TGF-beta 1. The application of TGF-beta 1 protein also increased the expression level of VEGF-A and -C. Knockdown with small interfering RNA (siRNA) targeting to TGF-beta 1 and the selective chemical inhibition (A83-01) to ALK5 confirmed the involvement of the TGF-beta signaling pathway in the 4-HR-mediated VEGFs expression. 4HR application in a burn model of diabetic rats demonstrated an increased level of angiogenic proteins with wound healing. Compared to sericin application, the 4HR application group showed more prominent capillary regeneration. Collectively, 4HR activated TGF-beta 1/ALK5/VEGFs signaling in endothelial cells and induced vascular regeneration and remodeling for wound healing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available